From chemoprevention and organ preservation programs to post-operative management: major achievements and strategies of the EORTC Head and Neck Cancer Group  by Langendijk, J.A. et al.
ejc supplements 10, no. 1 (2012) 76–81
From chemoprevention and organ preservation programs
to post-operative management: major achievements and
strategies of the EORTC Head and Neck Cancer Group
J.A. Langendijk *, L. Licitra , A. Psyrri , R. Knecht , G. Andry , C. Fortpied , R. Karraa, b c d e f
Gurunathf
a University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
b Instituto Nazionale Tumori, Milan, Italy
cAttikon Hospital, National Kapodistrian University of Athens, Greece
d Universitaets-Krankenhaus, Eppendorf, Hamburg, Germany
e Institut J. Bordet, Brussels, Belgium








Head and neck cancer, mostly of squamous cell
origin, ranks sixth among the most common cancers,
accounting for approximately 6% of all cases of
cancer. Each year, more than 500,000 new cases are
diagnosed worldwide. 1 Approximately 60% of patients
present with advanced disease (stages III and IV), for
which the prognosis is poor. The multimodal curative2
standard treatment of squamous cell carcinoma of the
head and neck (SCCHN) includes surgery followed by
adjuvant treatment (radiotherapy ± chemotherapy) or
primary radiotherapy in combination with chemotherapy
(concurrent chemoradiation or induction chemotherapy)
and/or targeted therapy. Despite this multimodality
intensiﬁed approach, more than 50% of patients with
locally advanced SCCHN will relapse. 3,4
* Corresponding author. J.A. Langendijk.
Tel.: +31 50 3615532; fax: +31 50 3611692.
E-mail address: j.a.langendijk@umcg.nl (J.A. Langendijk).
The European Organisation for Research andTreatment
of Cancer (EORTC) has been at the forefront of oncology
practice-changing trials throughout the world. The
EORTC Head and Neck Cancer Group (HNCG) was one
of the earliest EORTC disease-oriented groups to be
formed. The aim of the HNCG is to develop, conduct,
coordinate and stimulate clinical and translational
research, in head and neck cancer patients. The HNCG
mainly conducts multicenter prospective, randomized
studies that will potentially change clinical practice. The
HNCG comprises a well-balanced team representing all
medical specialties involved in head and neck cancer
treatment, including surgical oncology, maxillofacial
surgery, radiation oncology, medical oncology, pathology,
and radiology. This ensures and promotes harmonization
of all treatment modalities that can be offered to
patients.
The HNCG has contributed its might to practice-
changing trials, and the following is a reﬂection on what
has been achieved to date. It summarizes the landmark
trials that have signiﬁcantly modiﬁed the way head and
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neck cancer is understood and treated and have had a
beneﬁcial impact for the patients.
2. Major advances
2.1. Larynx preservation
The HNCG was a pioneer in the ﬁeld of organ
preservation starting with the initiation of the ﬁrst
larynx preservation trial (EORTC 24891). In 1986, the
HNCG initiated this randomized phase III trial in order
to investigate if larynx preservation could be achieved
among patients with histologically proven squamous
cell carcinomas of the piriform sinus or aryepiglottic
fold without hampering overall survival (OS). Preliminary
results were published in 1996 in a landmark paper in
J Natl Cancer Inst and the 10-year results were presented
as an abstract at ASCO 2004. 5
In this study, a total number of 202 patients were ran-
domly assigned to receive either the standard approach
at that time, which was primary surgery consisting of
total laryngectomy with partial pharyngectomy and neck
dissection followed by post-operative radiotherapy, or
the larynx preservation approach, including induction
chemotherapy by two cycles of induction chemotherapy
(cisplatin 100mg/m2 on day 1 and 5-ﬂuorouracil [5-FU]
1000mg/m2 on days 1−5) followed by a third cycle in
case of partial of complete response and subsequently
followed by conventional radiotherapy for complete
responders and conventional surgery followed by post-
operative radiotherapy in case there was no complete
response. The endpoints were OS, non-inferiority [haz-
ard ratio (preservation/surgery) 1.43, 1-sided a=0.05],
progression-free survival (PFS), and survival with a
functional larynx (SFL).
At a median follow-up of 10.5 years, there were
194 eligible patients included in the analysis. Disease
progression was seen in 54 and 49 patients in the
surgery and larynx preservation arm, and 81 and 83
patients had died, respectively. The 10-year OS rate was
13.8% in the surgery arm and 13.1% in the preservation
arm. The 10-year PFS rates were 8.5% and 10.8%,
respectively. Most importantly, in the entire group of
100 patients included in the larynx preservation arm, the
rates of patients with a functional larynx were 42% and
35% at three and ﬁve years, respectively.
This ﬁrst randomized trial on induction chemotherapy
for larynx preservation in advanced but resectable hy-
popharyngeal cancer has shown that larynx preservation
in locally advanced hypopharyngeal cancer is feasible
without jeopardizing OS. In addition, the EORTC adopted
induction chemotherapy followed by radiotherapy as
the new standard for the next EORTC study on larynx
preservation.
In addition to this study, the HNCG conducted a
second larynx preservation study (EORTC 24954) in
which patients with resectable advanced squamous cell
carcinoma of the larynx or hypopharynx were randomly
assigned to receive sequential chemotherapy followed
by conventional radiotherapy (as described above) or
alternating chemoradiation, consisting of four cycles of
cisplatin (100mg/m2 per day) and 5-FU (200mg/m2 per
day instead of 1000mg/m2 per day) in weeks 1, 4, 7, and 10
alternated with radiotherapy with 20Gy during the three
2-week intervals between chemotherapy cycles to a total
dose of 60Gy. In this study, the control arm was the same
as the experimental arm of EORTC protocol 24891, except
that there were four cycles of chemotherapy instead
of three cycles. All non-responders underwent salvage
surgery and post-operative radiotherapy. 6
In this study, a total number of 450 patients were
randomly assigned to either sequential or alternating
chemoradiation. The primary endpoint of this study was
SFL in place. After a median follow-up of 6.5 years, there
was a non-signiﬁcant trend towards better outcome
for the alternating arm. The 3-year SFL was 39.5% for
the sequential arm and 45.4% for the alternating arm.
The 5-year SFL was 30.5% for the sequential arm and
36.2% for the alternating arm. No signiﬁcant difference
was found between the two arms with regard to OS.
Grade 3 or 4 mucositis occurred in 32% of the 200 patients
in the sequential arm who received radiotherapy and
in 21% of the 220 patients in the alternating arm. Late
severe oedema and/or ﬁbrosis were observed in 16% of
the patients in the sequential arm and in 11% in the
alternating arm.
Based on these ﬁndings, it was concluded that larynx
preservation, progression-free interval, and OS were
similar in both arms, as were acute and late toxic
effects.
2.2. Induction chemotherapy
In the 1990’s, the results of phase II studies indicated
that docetaxel plus cisplatin and ﬂuorouracil (TPF) might
be more efﬁcacious than the classic regimen of cisplatin
plus ﬂuorouracil (PF). Therefore, the EORTC Head and
Neck Cancer Group conducted the EORTC 24971/TAX 323
study, comparing TPF with PF induction chemotherapy
followed by conventional radiotherapy in patients with
locoregionally advanced, unresectable squamous-cell
carcinoma of the head and neck. The results of this
landmark study were published in 2007 in the New
England Journal of Medicine. 4
In this study, patients were randomly assigned to
receive either TPF or PF. The TPF regimen consisted
of docetaxel at a dose of 75mg/m2 administered as a
1-hour infusion on day 1, followed by cisplatin at a
dose of 75mg/m2, administered as a 1-hour infusion
on day 1, and ﬂuorouracil at a dose of 750mg/m2 per
day, administered by continuous infusion on days 1−5.
The PF regimen consisted of cisplatin at a dose of
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100mg/m2, administered as a 1-hour infusion on day 1,
followed by ﬂuorouracil at a dose of 1000mg/m2 per
day, administered by continuous infusion on days 1−5.
Treatment was administered every 3 weeks (deﬁned as
one cycle) for up to 4 cycles, unless progressive disease,
unacceptable toxic effects, or withdrawal from the study
occurred earlier. During chemotherapy, patients were
monitored clinically and with laboratory tests on day 1
of each cycle before treatment. Imaging of tumours was
performed at the end of cycles 2 and 4.
Patients who did not have progressive disease and
who had adequate bone marrow function (neutrophil
count 2.0×103 cells/mm3; platelet count 100×103
cells/mm3; and hemoglobin 10 g/dl), complete resolu-
tion of mucositis for at least one week, and healing
from any dental procedures, underwent radiotherapy
within 4−7 weeks after the completion of chemotherapy.
Radiation was delivered during a 7-week period with
the use of either conventional fractionation (total dose,
66−70Gy) or accelerated or hyperfractionated regimens
(total maximum dose of 70Gy for the accelerated
regimen and 74Gy for the hyperfractionated regimen).
The primary endpoint of this study was PFS. Secondary
endpoints were OS, best overall response rate after
induction chemotherapy and after radiation therapy,
duration of response, time to treatment failure, toxic
effects, and health-related quality of life, as reported
previously.
This study showed that TPF induction chemotherapy
resulted in signiﬁcant and clinical meaningful improve-
ments in outcomes, as compared with PF induction
chemotherapy, in locoregionally advanced, unresectable
SCCHN. Patients who were treated with TPF had a
reduction of 28% in the risk of disease progression or
death, as compared with those who received PF. They
also had an extension of 2.8 months in median PFS. This
result was associated with signiﬁcant improvements in
OS, overall response rates, and time to treatment failure.
Patients in the TPF group had a reduction of 27% in
the risk of death, an improvement in median OS of
4.3 months, and an absolute increase in 3-year survival
of 10.9%.
2.2.1. Long-term follow up
Recently, long-term data were collected and analyzed
using the Cox proportional hazard model adjusted for
treatment, tumor site, T-classiﬁcation, N-classiﬁcation
and performance status. In this updated analysis, the PFS
remained signiﬁcantly better with TPF compared with
PF (hazard ratio [HR] unadjusted 0.71 [95%CI: 0.57–0.89],
p = 0.003, medians of 12.7 versus 8.6 months, and 5-year
PFS 22.9% versus 13.5%, mainly due to less locoregional
progression). A similar picture was observed for OS (HR
unadjusted 0.74 [95%CI: 0.59–0.94], p = 0.011, medians of
18.8 versus 14.5 months, 5-year OS 27.5 versus 18.6%).
Long-term side effects in the TPF versus PF arm were:
7.3% versus 5.0% for tracheotomy; 3.4% versus 5.5% feed-
ing tube dependence; 10.7% versus 10.5% for gastrostomy,
and 7.9% versus 3.3% for second malignancies.
The long-term data on survival and long-term side
effects (feeding tube dependency, tracheotomy, gastros-
tomy and second malignancies) with a median follow-
up of 8.6 years were presented at ASCO 2011. The results
consistently showed survival advantage for the TPF arm
and supported the conclusions of the ﬁnal analysis that
TPF is superior to PF as induction chemotherapy regimen
for patients with unresectable SCCHN.
2.3. Post-operative chemoradiotherapy
The HNCG also pioneered the concept of post-operative
chemoradiation for treatment of stage III or IV resected
head and neck cancer. This trial, EORTC 22931, was
published in the New England Journal of Medicine in 2004. 7
The primary objective of this study was to investigate
the additional value of concomitant chemotherapy to
standard post-operative radiotherapy.
In this phase III study, a total number of 334 patients
with curatively resected SCCHN were randomly assigned
to receive post-operative radiotherapy alone (66Gy over a
period of 6 weeks) or the same post-operative radiother-
apy regimen combined with concurrent chemotherapy
consisting of cisplatin (100mg/m2 on days 1, 22, and 43
during radiation). The primary endpoint was PFS.
After a median follow-up of 60 months, the 5-year PFS
was 47% after post-operative chemoradiation which was
signiﬁcantly better than the 36% observed after post-
operative radiotherapy alone (P = 0.02; HR 0.75 [95%CI:
0.56−0.99). In addition, the OS rate was also signiﬁcantly
higher in the chemoradiation group than in the
radiotherapy group (P=0.04; HR for death, 0.70; 95%CI:
0.52−0.95), with 5-year Kaplan–Meier estimates of OS
of 53% and 40%, respectively. The cumulative incidence
of local or regional relapses was signiﬁcantly lower in
the combined-therapy group (P=0.007). The estimated
5-year cumulative incidence of local or regional relapses
(considering death from other causes as a competing
risk) was 31% after radiotherapy and 18% after combined
therapy. Severe (grade 3 or higher) adverse effects were
more frequent after combined therapy (41 percent) than
after radiotherapy (21 percent, P = 0.001); the types of
severe mucosal adverse effects were similar in the two
groups, as was the incidence of late adverse effects.
The results conﬁrmed that post-operative concurrent
administration of high-dose cisplatin with radiotherapy
is more efﬁcacious than radiotherapy alone in patients
with locally advanced head and neck cancer, and does
not cause an undue number of late complications. The
results of this study were combined with those from a
similar study conducted by the RTOG (RTOG study 9501)
in a joined analysis, which showed that the addition of
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concomitant chemotherapy in the post-operative setting
was particularly efﬁcacious in case of positive surgical
margins and/or lymph node metastases with extranodal
spread, which has now become the current standard in
these cases. 8
3. Translational research
The HNCG has a good translational research (TR)
component exploring the various molecular mechanisms
underlying SCCHN as well as the predictors for response
and resistance. Tissue banks from large prospective
clinical trials, such as those conducted by EORTC,
represent precious resources for validation of biomarkers
before their clinical implementation. EORTC has de-
veloped standardized protocols for specimen collection,
processing, and storage.
In the previous decades SCCHN was regarded as
a single disease entity. However, advances in molec-
ular biology tools with the widespread application
of genomic and proteomic approaches have revealed
that distinct prognostic subclasses exist beyond those
deﬁned by TNM stage. 9 For example, several lines of
epidemiological, molecular pathology and experimental
evidence suggest that Human Papillomavirus (HPV),
especially type 16, are causally associated with a subset
of oropharyngeal squamous cell carcinomas. 10 HPV-
associated SCCHN represent a distinct clinical entity in
terms of biology and clinical behaviour. HPV-associated
SCCHN expresses E6 and E7 viral oncoproteins which
bind and degrade p53 and retinoblastoma (pRb) tumor
suppressor proteins, respectively. A negative autoregu-
latory loop between p16 and pRb has been reported;
low pRb protein levels of HPV-induced tumors lead to
p16 protein overexpression. Therefore, HPV-associated
SCCHN contain high p16 protein levels. p16 positivity
is used as a surrogate marker for biologically and
clinically meaningful HPV infection. 11 From the clinical
perspective, HPV positivity confers 50−80% reduction in
risk of disease failure compared to tobacco-associated
SCCHN. 12−14 The contribution of therapy selection in the
observed survival beneﬁt, however, is unclear. Therefore,
it is possible that patients with HPV-associated SCCHN
are exposed to unnecessary overtreatment. Clinical trials
studying treatment deintensiﬁcation in the HPV-positive
subgroup are currently being undertaken. In this context,
several TR projects are planned by HNCG. First, we
plan to retrospectively analyze oropharyngeal cancer
specimens from patients included in the EORTC 24971 for
tumor HPV and p16 status and to correlate results with
treatment outcome per study arm. This retrospective
analysis will hopefully provide us with valuable results
that will be validated in the setting of a prospective trial.
The question we aim to answer is whether the addition
of docetaxel to PF provides additional beneﬁt in the
HPV+/p16+ patient subgroup. Patients participating in
the EORTC 22071–24071 post-operative study will be sub-
jected to prospective p16 determination to demonstrate
whether p16+ patients with high risk features derive
survival gain with the incorporation of panitumumab to
standard post-operative cisplatin chemoradiotherapy.
Epidermal growth factor receptor (EGFR) signaling
network is pivotal for SCCHN growth and survival. 15−17
Despite the vast amount of experimental and clinical
evidence supporting the use of EGFR-targeted therapy
in SCCHN, single-modality treatment with these agents
in unselected clinical trials is associated with modest
results. The most intriguing research question in
EGFR-targeted therapy in SCCHN is patient selection.
Mechanisms of resistance to EGFR-targeted therapies
have been identiﬁed in other tumors. In colon cancer, for
example, KRAS mutations are associated with resistance
to cetuximab and panitumumab. The HNCG has initiated
window of opportunity studies that will serve as a
platform to identify new relevant molecular targeted
therapies in SCCHN and to collect biological samples to
better understand treatment resistance. For this purpose,
new promising compounds will be tested in the pre-
operative window setting to resolve some of these issues
and maximize the chance of observing tumor response.
In addition, the collection of biopsies before treatment at
the time of diagnosis and after treatment at the time of
surgery will permit the assessment of predictive molec-
ular markers and may help in identifying subgroups of
patients most likely to respond to therapy.
Genetic factors may affect response or toxicity to
chemotherapy and radiotherapy. Platinum is widely
used to treat SCCHN although a substantial proportion
of patients fail to respond to treatment, and initial
responders remain at risk for disease progression or
recurrence. Genetic variations that play a role in
cellular repair of drug-induced DNA damage may affect
patient response to chemotherapy. Understanding these
variations may improve outcomes by allowing oncol-
ogists to optimize treatment based on each patient’s
genetic and molecular background. Excision repair cross-
complementation group 1 (ERCC1) is a DNA repair gene
in the nucleotide excision repair (NER) pathway that
is activated when platinum-based chemotherapy drugs,
such as cisplatin and carboplatin, form DNA adducts. The
relation between ERCC1 mRNA and protein expression
and resistance to platinum has been demonstrated in
prospective and retrospective studies in patients with
advanced-stage gastric, ovarian, colorectal, esophageal,
and non-small-cell lung cancers but it has not been
clearly shown in SCCHN. The HNCG is planning to
determine the impact of ERCC1 gene polymorphisms and
protein expression on PFS of patients who participated in
the EORTC 22931 phase III clinical trial.
In addition to aforementioned projects, several other
TR proposals will be conducted in the future on
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biospecimens of the tissue banks from prospective
studies. The aim is to shed light to the biology of the
disease, identify prognostic subclasses and predictors for
response or toxicity to therapy in order to increase cure
rates.
4. Collaborations with other groups in intergroup
studies
Joint sessions with the EORTC Radiation Oncology Group
during the EORTC Groups Annual Meetings are currently
standard. A fruitful discussion with the members
of the EORTC Radiation Oncology Group resulted in
several common proposals with this group. In addition,
a number of meetings have taken place between
representatives of both groups, which resulted in new
plans for future collaborations.
There is an ongoing collaboration with other groups
within the EORTC frame work. Since 2008, the HNCG
meetings started with speciﬁc subcommittee meetings
for translational research, imaging and quality of life.
The main objective of these sessions was to enhance
the collaboration with other groups and to stimulate
integration of additional studies to the phase II and
phase III studies under construction. More speciﬁcally,
a number of translational research projects have been
conducted by the group using either information from
existing databases of former clinical studies or data that
will be derived from future clinical studies. Together with
the EORTC Imaging Group, the aim is to conduct add-on
studies to future phase III studies. Finally, the group
collaborates with the EORTC Quality of Life Group on the
development of a new and revised version of the head
and neck quality of life module to assess quality of life.
5. Future strategy
The HNCG has developed strategies to promote patient-
oriented laboratory research, and they recently sum-
marized ongoing and planned clinical trials, outlined
planned translational research projects, and described
strategies to promote translational head and neck cancer
research, which will include the following issues for
future clinical studies:
• There will be a close collaboration with the EORTC
Radiation Oncology Group, in particular for new studies
in the primary setting in which radiotherapy is part
of the treatment regimens. In particular, the EORTC
Radiation Oncology Group will play an important role
in Quality Assurance of radiotherapy in all future
clinical studies;
• Prospective tissue collection and biobanking from
patients treated in future clinical trials will be routinely
performed for translational research purposes, e.g. in
order to identify prognostic and in particular predictive
factors and to generate hypotheses for future clinical
trials in SCCHN;
• In order to do this efﬁciently, increased collaboration
between the basic scientists of the EORTCTranslational
Research Division interested in head and neck cancer
research and the physicians of the HNCG will be
enhanced;
• The initiation of trials with novel methodology like
windows of opportunity study will test the feasibility,
efﬁcacy and safety of targeted agents in the pre-
operative setting;
• HPV-positive SCCHN should be considered a separate
entity with a more favourable prognosis than the
HPV-negative subpopulation. For patients with HPV-
positive oropharyngeal cancer, future trials will focus
on the development of less toxic regimens with
similar efﬁcacy, either in collaboration with other
international groups or within the EORTC framework
using alternative statistical study designs. For the
subset of patients with HPV-negative tumors, separate
trials will be conducted in which the value of
new regimens containing taxanes and EGFR-inhibitors
combined with modern radiation techniques will be
further explored;
• Given the results obtained among patients at interme-
diate risk after primary surgery and given the number
of patients that can be included in such studies, it will
be unlikely that phase III studies in the intermediate-
risk subset will be feasible from a statistical point of
view. Therefore, studies in the post-operative setting
will embark on the results of the EORTC 22931 and will
mainly focus on the high-risk patients;
• New steps are taken to design and initiate clinical
trials in rare tumors like salivary gland cancer,
nasopharyngeal cancer and paranasal sinus tumors.
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